Latest Content

Lombard Risk Management

Positive market and encouraging pipeline

After such an outstanding close to FY17, it was almost inevitable that Q1’18 was going to be somewhat quieter for new license orders. This happens most years (see below) as the pipeline is naturally replenished following a strong Q4. Typically leading to a 35%- 45% vs 65%-55% revenue split across H1:H2. We suspect FY18 will be no different, albeit perhaps pitched towards the bottom of the range.

 View

  • 19 Jul 17

Tristel

US market squarely in the cross-hairs

One golden rule of investing is not to ‘count chickens’. A prudent view that we’ve adopted when modelling Tristel’s application to the EPA/FDA to launch chlorine dioxide (Clo2) based infection, hygiene and contamination control products in the US. Whilst our approach is admirable, there is nonetheless a danger of us being too conservative for too long. Especially when, in Tristel’s case, the opportunity of accessing the world’s biggest healthcare market is now almost within striking distance.

 View

  • 19 Jul 17

Venture Life Group

Delivering strong revenue momentum

VLG reports strong revenue growth of 28% to £7.8m in the H117 period – or 18% on a like-for-like basis – as investment in promotion of the UltraDEX oral care range paid off, indicating that VLG is well on track to deliver our FY17 estimated revenue. We estimate that line extensions, prospects of further international expansion of the brand, will be a key driver of future margin and revenue growth. There are also indications that the Biokosmes manufacturing site is increasing output and revenues, having achieved a record high in sales in June. We maintain our forecasts ahead of FY17 results.

 View

  • 13 Jul 17

CLEARSTAR

Booming ‘gig’ economy driving growth

Don’t you just love ‘Tech’? Churning out irresistible growth rates, profit margins and cashflows, allied to robust visibility and high client retention. A compelling mix. The only problem is that many others do as well, pushing valuations to often nose-bleed levels.

 View

  • 12 Jul 17

Accrol Group

Building a robust platform

FY17 results, broadly as forecast, capped a strong first year since IPO. Accrol held gross margins in a challenging market. It was helped by a strong position as a key supplier to UK Discounters – and grew its share from 35% to 50% - well-timed currency hedges and a lean operational model which gives it access to materially better raw material prices than its competition.

 View

  • 11 Jul 17

Benchmark

Creating a strong platform for growth

Highlights of H1’17 included the strong performance in Breeding & Genetics, sales up 76% with recovery in sales of salmon eggs to Chile, and growth in sales volumes and prices in other markets and species. BMK also laid down further ground roots for expansion, including formation of collaboration with Salmar ASA, a leading salmon producer, validation of BMK’s expertise through the life cycle of the salmon from broodstock to grow-out, and across its entire range of technologies.

 View

  • 07 Jul 17
 

Equity Development Research and Daily Commentaries

Research Tree offers Equity Development research, providing ongoing coverage of 44 shares. We offer 210 reports from Equity Development on Research Tree.

  • Research reports provided by Equity Development

  • Companies covered by Equity Development

  • Sectors covered by Equity Development


Related Content

View the latest research on other companies in the sector. 

Fastforward Innovations

Firing on all cylinders

Being able to consistently deliver out-sized investment returns, is all about managing risk and finding high quality, growth stocks at the right price. We’ve seen this already in 2016 with many such smallcaps, like Keywords Studios, Fevertree Drinks, Boohoo, GW Pharmaceuticals and Tristel. Another stock we think that in due course could join this select band, is FastForward (up 100% since mid Oct’15) which invests exclusively in rapidly expanding technology firms. Today FFWD holds non-controlling positions in nine such privately owned businesses, which we understand are all either meeting or exceeding their internal plans. Here, progress was said to be “incredibly positive and very encouraging” yesterday, with updates being released in relation to three of them.

 View

  • 30 Nov 16
  • -
  • -